BioMarin Pharmaceutical (NASDAQ:BMRN) Issues Earnings Results

BioMarin Pharmaceutical (NASDAQ:BMRN) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18, Zacks reports. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 10.10%. The company had revenue of $747.31 million during the quarter, compared to analysts’ expectations of $711.05 million. BioMarin Pharmaceutical updated its FY 2025 guidance to 4.200-4.400 EPS.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $68.73 on Friday. The company’s 50-day moving average is $64.84 and its two-hundred day moving average is $71.05. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. BioMarin Pharmaceutical has a 1-year low of $60.63 and a 1-year high of $94.85. The firm has a market capitalization of $13.10 billion, a price-to-earnings ratio of 31.24, a PEG ratio of 0.58 and a beta of 0.28.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. William Blair cut shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 30th. Wedbush reissued an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday. Wolfe Research assumed coverage on shares of BioMarin Pharmaceutical in a research note on Friday, November 15th. They set an “outperform” rating and a $95.00 target price for the company. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 11th. Finally, Scotiabank boosted their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a “sector perform” rating in a research note on Thursday. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $93.81.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.